Who Needs Closer Monitoring for Reglan-Related Tardive Dyskinesia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Targeted Legal Awareness

If you or a loved one has taken Reglan for a gastrointestinal condition, you may be concerned about the risk of tardive dyskinesia—a potentially irreversible movement disorder. Understanding who is most vulnerable can help guide informed discussions with your healthcare provider. The legacy of medical research has long emphasized the importance of patient-specific risk factors in medication safety, and this page reviews the FDA Adverse Event Reporting System data to clarify warning signs and monitoring recommendations.

The Medical Reality: Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a prescription medication approved for short-term use in adults with symptomatic gastroesophageal reflux (4 to 12 weeks) and for relief of symptoms in acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the prescribing information advises using the drug for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, total treatment duration should not exceed 12 weeks; if longer use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug is not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities, which can be disfiguring and potentially irreversible (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may also suppress or partially suppress signs of TD, potentially delaying diagnosis by masking the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The mechanistic pathway linking Reglan to TD involves dopamine receptor blockade in the basal ganglia, leading to supersensitivity of dopamine receptors and subsequent involuntary movements. This effect is dose-dependent and cumulative, with longer exposure increasing risk.

Statute of Limitations for Reglan Claims in New York

For patients in New York considering legal action related to Reglan-induced TD, the statute of limitations is a critical factor. In New York, personal injury claims generally must be filed within three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For TD, the timeline between exposure and documented harm can be variable, as symptoms may develop months or years after starting Reglan. The boxed warning emphasizes that TD can occur after short-term use, but risk increases with longer treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients should document the date of first Reglan use, duration of therapy, and date of TD diagnosis to establish the timeline for statute of limitations purposes. Settlement considerations for affected patients include the adequacy of warnings provided by manufacturers. The FDA-approved labeling includes a boxed warning about TD risk, but patients may argue that prescribers or patients were not adequately informed about the potential for irreversible harm, especially given the drug's approval for short-term use only. The warning states that Reglan should be used for the shortest duration and that treatment for gastroesophageal reflux should not exceed 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If a patient was prescribed Reglan for longer than recommended, this could strengthen a claim regarding inadequate warnings or failure to monitor. Patients should also consider that TD may be misdiagnosed or attributed to other conditions, delaying recognition of the link to Reglan. The warning notes that metoclopramide can mask TD symptoms, complicating diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Medical records should be reviewed to determine when TD symptoms first appeared and whether they were documented as related to Reglan. In summary, the evidence establishes a clear causal link between Reglan and TD, with risk increasing with duration and cumulative dose. New York patients must be aware of the statute of limitations, which typically runs from discovery of injury. Settlement outcomes may depend on the adequacy of warnings, duration of Reglan use, and timing of TD diagnosis. Legal consultation is recommended to assess individual circumstances.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan tardive dyskinesia claims in New York?

In New York, personal injury claims generally must be filed within three years from the date of injury or from when the injury was discovered or should have been discovered with reasonable diligence. For tardive dyskinesia caused by Reglan, the clock typically starts when the patient discovers or reasonably should have discovered the link between the drug and their symptoms.

Can I still file a claim if my tardive dyskinesia was diagnosed years after stopping Reglan?

Yes, if the diagnosis occurred later and you could not have reasonably discovered the injury earlier, the statute of limitations may begin at the time of diagnosis. However, it is crucial to consult with an attorney promptly to evaluate your specific timeline and preserve your rights.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.